Clinical Study on Suibai No.1 Prescription Combined with Chemotherapy for Treatment of Acute Myeloid Leukemia

PAN Ming, GU Gangshou, HUANG Jianxia, WANG Yan, WU Qing, DU Minghu, WU Binzhang, HU Xingjiang, XIE Huanrong

PAN Ming, GU Gangshou, HUANG Jianxia, WANG Yan, WU Qing,

DU Minghu, WU Binzhang, HU Xingjiang, XIE Huanrong

Department of Hematology, People's Hospital of Wuwei City, Wuwei 733000, China

Abstract: Objective To observe the clinical efficacy of Suibai No.1 Prescription combined with chemotherapy for the treatment of acute myeloid leukemia (AML) and its effects on chemotoxic side effects. Methods Totally 60 AML patients were divided into treatment group and control group according to random number table method, with

30 cases in each group. Patients in the control group were treated with international standard chemotherapy (DA or IDA scheme), and treatment group were given Suibai No.1 Prescription on the basis of the control group, one dosage per day, twice a day, dissolved. Three weeks were one treatment course and the treatment for both groups lasted for two courses. Objective remission rate, TCM efficacy, toxic side effects, and complications of both groups were compared. Results The objective remission rate was 83.3% (25/30) in the treatment group and 66.7% (20/30) in the control group. The total effective rate of TCM efficacy was 96.7% (29/30) in the treatment group and 70.0% in the control group (21/30). The treatment group was significantly better than the control group (P<0.05). Compared with before treatment, the WBC levels of the two groups decreased significantly, and the levels of Hb, RBC and PLT significantly increased (P<0.05). After treatment, the WBC level in the treatment group was significantly lower than that in the control group, and the levels of Hb, RBC and PLT were significantly higher than those in the control group

(P<0.05). The incidence of gastrointestinal reactions, liver function damage and infection complications in the treatment group were lower than those in the control group (P<0.05). Conclusion Suibai No.1 Prescription combined with chemotherapy for the treatment of AML can effectively reduce the complications of AML and improve clinical efficacy and life quality of patients.

Keywords: acute myeloid leukemia; integrated traditional Chinese and Western medicine; Suibai No.1 Prescription; chemotherapy; clinical study